Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 483

1.

Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology.

Fagan AM, Shaw LM, Xiong C, Vanderstichele H, Mintun MA, Trojanowski JQ, Coart E, Morris JC, Holtzman DM.

Arch Neurol. 2011 Sep;68(9):1137-44. doi: 10.1001/archneurol.2011.105. Epub 2011 May 9.

PMID:
21555603
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia.

Le Bastard N, Coart E, Vanderstichele H, Vanmechelen E, Martin JJ, Engelborghs S.

J Alzheimers Dis. 2013;33(1):117-31. doi: 10.3233/JAD-2012-121246.

PMID:
22936010
[PubMed - indexed for MEDLINE]
3.

Comparison of cerebrospinal fluid levels of tau and Aβ 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms.

Irwin DJ, McMillan CT, Toledo JB, Arnold SE, Shaw LM, Wang LS, Van Deerlin V, Lee VM, Trojanowski JQ, Grossman M.

Arch Neurol. 2012 Aug;69(8):1018-25. doi: 10.1001/archneurol.2012.26.

PMID:
22490326
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI.

Shaw LM, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K, Soares H, Simon AJ, Lewczuk P, Dean RA, Siemers E, Potter W, Lee VM, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Acta Neuropathol. 2011 May;121(5):597-609. doi: 10.1007/s00401-011-0808-0. Epub 2011 Feb 11.

PMID:
21311900
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings.

Petrie EC, Cross DJ, Galasko D, Schellenberg GD, Raskind MA, Peskind ER, Minoshima S.

Arch Neurol. 2009 May;66(5):632-7. doi: 10.1001/archneurol.2009.59.

PMID:
19433663
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.

Kang JH, Vanderstichele H, Trojanowski JQ, Shaw LM.

Methods. 2012 Apr;56(4):484-93. doi: 10.1016/j.ymeth.2012.03.023. Epub 2012 Apr 6. Review.

PMID:
22503777
[PubMed - indexed for MEDLINE]
7.

Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.

Thaweepoksomboon J, Senanarong V, Poungvarin N, Chakorn T, Siwasariyanon N, Washirutmangkur L, Udompunthuruk S.

J Med Assoc Thai. 2011 Feb;94 Suppl 1:S77-83.

PMID:
21721431
[PubMed - indexed for MEDLINE]
8.

Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type.

Snider BJ, Fagan AM, Roe C, Shah AR, Grant EA, Xiong C, Morris JC, Holtzman DM.

Arch Neurol. 2009 May;66(5):638-45. doi: 10.1001/archneurol.2009.55.

PMID:
19433664
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.

Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, Waligórska T, Taylor P, Pan S, Frasier M, Marek K, Kieburtz K, Jennings D, Simuni T, Tanner CM, Singleton A, Toga AW, Chowdhury S, Mollenhauer B, Trojanowski JQ, Shaw LM; Parkinson's Progression Markers Initiative.

JAMA Neurol. 2013 Oct;70(10):1277-87.

PMID:
23979011
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.

Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T.

Arch Neurol. 2009 Mar;66(3):382-9. doi: 10.1001/archneurol.2008.596.

PMID:
19273758
[PubMed - indexed for MEDLINE]
11.

Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.

Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, Bergeson J, Manetti GJ, Zimmermann M, Tang B, Bartko JJ, Cohen RM.

JAMA. 2003 Apr 23-30;289(16):2094-103. Erratum in: JAMA. 2007 Oct 3;298(13):1516.

PMID:
12709467
[PubMed - indexed for MEDLINE]
12.

Cerebrospinal fluid Aβ1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels.

Slaets S, Le Bastard N, Martin JJ, Sleegers K, Van Broeckhoven C, De Deyn PP, Engelborghs S.

J Alzheimers Dis. 2013;36(4):759-67. doi: 10.3233/JAD-130107.

PMID:
23666174
[PubMed - indexed for MEDLINE]
13.

APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.

Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA.

Ann Neurol. 2010 Jan;67(1):122-31. doi: 10.1002/ana.21843.

PMID:
20186853
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Cerebrospinal fluid proteins predict longitudinal hippocampal degeneration in early-stage dementia of the Alzheimer type.

Wang L, Fagan AM, Shah AR, Beg MF, Csernansky JG, Morris JC, Holtzman DM.

Alzheimer Dis Assoc Disord. 2012 Oct-Dec;26(4):314-21. doi: 10.1097/WAD.0b013e31823c0cf4.

PMID:
22156755
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Comparison of xMAP and ELISA assays for detecting cerebrospinal fluid biomarkers of Alzheimer's disease.

Wang LS, Leung YY, Chang SK, Leight S, Knapik-Czajka M, Baek Y, Shaw LM, Lee VM, Trojanowski JQ, Clark CM.

J Alzheimers Dis. 2012;31(2):439-45. doi: 10.3233/JAD-2012-120082.

PMID:
22571982
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study.

Jongbloed W, Kester MI, van der Flier WM, Veerhuis R, Scheltens P, Blankenstein MA, Teunissen CE.

Alzheimers Dement. 2013 May;9(3):276-83. doi: 10.1016/j.jalz.2012.01.004. Epub 2012 Oct 27.

PMID:
23110867
[PubMed - indexed for MEDLINE]
17.

Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI.

Toledo JB, Xie SX, Trojanowski JQ, Shaw LM.

Acta Neuropathol. 2013 Nov;126(5):659-70. doi: 10.1007/s00401-013-1151-4. Epub 2013 Jun 29.

PMID:
23812320
[PubMed - indexed for MEDLINE]
18.

Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment.

Parnetti L, Chiasserini D, Eusebi P, Giannandrea D, Bellomo G, De Carlo C, Padiglioni C, Mastrocola S, Lisetti V, Calabresi P.

J Alzheimers Dis. 2012;29(1):229-38. doi: 10.3233/JAD-2011-111349.

PMID:
22232006
[PubMed - indexed for MEDLINE]
19.

Cerebrospinal fluid biomarkers, education, brain volume, and future cognition.

Roe CM, Fagan AM, Grant EA, Marcus DS, Benzinger TL, Mintun MA, Holtzman DM, Morris JC.

Arch Neurol. 2011 Sep;68(9):1145-51. doi: 10.1001/archneurol.2011.192.

PMID:
21911695
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

CSF biomarkers in frontotemporal lobar degeneration with known pathology.

Bian H, Van Swieten JC, Leight S, Massimo L, Wood E, Forman M, Moore P, de Koning I, Clark CM, Rosso S, Trojanowski J, Lee VM, Grossman M.

Neurology. 2008 May 6;70(19 Pt 2):1827-35. doi: 10.1212/01.wnl.0000311445.21321.fc.

PMID:
18458217
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk